Sinil Pharmaceutical Co., Ltd. (KOSDAQ: 012790)

Sinil Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	96,516	89,135	80,007	61,754	61,438	60,648
Other Revenue	-	-	-0	-	-	-
Revenue	96,516	89,135	80,007	61,754	61,438	60,648
Revenue Growth (YoY)	18.92%	11.41%	29.56%	0.51%	1.30%	13.84%
Cost of Revenue	54,811	51,565	44,362	37,313	37,234	35,773
Gross Profit	41,705	37,570	35,645	24,441	24,204	24,875
Selling, General & Admin	20,519	19,491	17,623	15,574	15,522	14,299
Research & Development	2,712	2,979	3,264	194.52	784.55	529.9
Other Operating Expenses	334.54	355.82	378.68	374.75	395.92	318.73
Operating Expenses	25,097	23,579	21,989	16,459	17,583	15,461
Operating Income	16,608	13,991	13,656	7,982	6,621	9,415
Interest Expense	-27.44	-26.13	-6.05	-9.72	-13.24	-216.82
Interest & Investment Income	868.05	849.37	352.84	184.48	224.04	426.73
Currency Exchange Gain (Loss)	-71.16	-59.59	90.91	26.14	4.22	-0.77
Other Non Operating Income (Expenses)	1,212	1,379	899.91	14.64	1,226	-1,028
EBT Excluding Unusual Items	18,589	16,134	14,994	8,197	8,062	8,595
Gain (Loss) on Sale of Investments	-	-532.61	-478.44	115.48	-11.37	-15.66
Gain (Loss) on Sale of Assets	-636.73	-641.55	221.3	14	13.42	-219.89
Asset Writedown	-7	-7	-92.08	14.5	97.5	-14.57
Pretax Income	17,945	14,953	14,645	8,341	8,162	8,345
Income Tax Expense	2,182	1,312	2,488	1,663	617.51	1,088
Net Income	15,763	13,641	12,157	6,679	7,544	7,257
Net Income to Common	15,763	13,641	12,157	6,679	7,544	7,257
Net Income Growth	35.73%	12.21%	82.02%	-11.47%	3.96%	27.01%
Shares Outstanding (Basic)	12	12	12	11	11	11
Shares Outstanding (Diluted)	12	12	12	11	11	11
Shares Change (YoY)	-0.08%	-0.04%	3.91%	-0.97%	-0.08%	-2.92%
EPS (Basic)	1363.79	1179.82	1051.00	600.00	671.15	645.07
EPS (Diluted)	1363.79	1179.82	1051.00	600.00	671.15	645.07
EPS Growth	35.84%	12.26%	75.17%	-10.60%	4.04%	30.83%
Free Cash Flow	16,038	1,551	3,336	7,820	2,261	2,576
Free Cash Flow Per Share	1387.60	134.13	288.44	702.52	201.11	228.96
Gross Margin	43.21%	42.15%	44.55%	39.58%	39.40%	41.02%
Operating Margin	17.21%	15.70%	17.07%	12.93%	10.78%	15.52%
Profit Margin	16.33%	15.30%	15.20%	10.82%	12.28%	11.97%
Free Cash Flow Margin	16.62%	1.74%	4.17%	12.66%	3.68%	4.25%
EBITDA	22,301	19,353	18,088	12,518	11,053	13,697
EBITDA Margin	23.11%	21.71%	22.61%	20.27%	17.99%	22.58%
D&A For EBITDA	5,693	5,361	4,432	4,536	4,432	4,282
EBIT	16,608	13,991	13,656	7,982	6,621	9,415
EBIT Margin	17.21%	15.70%	17.07%	12.93%	10.78%	15.52%
Effective Tax Rate	12.16%	8.77%	16.99%	19.93%	7.57%	13.04%
Advertising Expenses	-	1,059	762.13	157.25	206.15	266.98

Source: S&P Capital IQ. Standard template. Financial Sources.